Clinical trials · North Carolina
Cancer clinical trials in North Carolina
We’re tracking 622 recruiting cancer studies with a site in North Carolina — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in North Carolina
- NCT07281417RecruitingPhase 2
Testing adding cemiplimab to chemo before surgery for sinus cancer
This trial tests whether adding the immunotherapy drug cemiplimab to standard chemotherapy before surgery helps treat sinonasal squamous cell carcinoma. The goal is to see if this combination reduces tumors more effectively than chemotherapy alone.
Chapel Hill, North CarolinaAges 18 years+ - NCT07225127Recruiting
Bladder cancer treatment: therapy vs. surgery
This study compares two standard treatments for high-grade non-muscle-invasive bladder cancer that has come back after initial treatment: medication placed directly into the bladder (intravesical therapy) or bladder removal surgery (cystectomy). The goal is to see which option works better for patients like you.
Chapel Hill, North CarolinaAges 18 years+ - NCT07216456Recruiting
Vaginal dilator therapy after pelvic radiation
This trial tests a program to help women use vaginal dilators after finishing pelvic radiation for cancers like cervical or anal cancer. It aims to improve vaginal health and quality of life.
Durham, North CarolinaAges 18 years+ - NCT07214610Recruiting
Improving breast cancer outcomes in North Carolina
This study looks at why some women with invasive breast cancer do better than others. It combines information from biology, medical history, and lifestyle to find ways to improve care and outcomes.
Chapel Hill, North CarolinaAges 20–74 - NCT07127874RecruitingPhase 1
Study of PHN-012 for advanced solid tumors
This trial tests a new drug called PHN-012 for people with advanced colorectal, non-small cell lung, or pancreatic cancer who have already tried at least one standard treatment. The goal is to see if the drug can help shrink or slow tumor growth.
Durham, North CarolinaAges 18 years+ - NCT07109726RecruitingPhase 1/Phase 2
Testing TER-2013 for advanced tumors with AKT/PI3K/PTEN changes
This trial tests a new drug called TER-2013, alone or combined with another drug (fulvestrant), for people with advanced solid tumors that have specific genetic changes in the AKT/PI3K/PTEN pathway. It aims to see if the drug is safe and effective.
Huntersville, North CarolinaAges 18 years+ - NCT07028853RecruitingPhase 3
New drug combo for advanced prostate cancer
This study tests whether adding the investigational drug mevrometostat to the standard treatment enzalutamide works better than enzalutamide alone for men with prostate cancer that has spread to other parts of the body (metastatic castration-sensitive prostate cancer). You may benefit if you haven't yet received chemotherapy or similar strong treatments for this stage of cancer.
Cary, North CarolinaAges 18 years+ - NCT07030257RecruitingPhase 1/Phase 2
Study of CP-383 for advanced solid tumors
This study tests a new drug called CP-383 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors or slow cancer growth, especially for certain cancers with genetic changes.
Huntersville, North CarolinaAges 18 years+ - NCT06998940RecruitingPhase 3
Chemotherapy with or without panitumumab for pancreatic cancer
This trial tests whether adding a targeted drug called panitumumab to standard chemotherapy can help people with a certain type of pancreatic cancer that has spread. It is for patients whose tumors do not have a KRAS mutation and who have already had one line of chemotherapy.
Pinehurst, North CarolinaAges 18 years+ - NCT06965192Recruiting
Visual tools for cancer surgeon decision-making
This trial tests visual tools to help surgeons make better decisions for patients with early-stage prostate or kidney cancer. It may help you and your doctor choose the best treatment.
Wilmington, North CarolinaAges 18 years+ - NCT06958328RecruitingPhase 3
Higher dose radiation for locally advanced pancreatic cancer
This trial tests whether giving a higher dose of radiation to the pancreas is safe and effective for people with locally advanced pancreatic cancer who have already had chemotherapy without progression.
Chapel Hill, North CarolinaAges 18 years+ - NCT06901531RecruitingPhase 3
Study of zolbetuximab with pembrolizumab and chemo for gastric cancer
This trial tests a new combination of drugs (zolbetuximab, pembrolizumab, and chemotherapy) for people with advanced stomach or gastroesophageal junction cancer. It may be an option if your tumor has certain proteins (CLDN18.2 and PD-L1) and you haven't had chemotherapy for advanced disease.
Durham, North CarolinaAges 18 years+ - NCT06902376RecruitingPhase 1
XL092 and cemiplimab for advanced thyroid cancer without BRAF mutation
This trial tests a combination of two drugs, XL092 and cemiplimab, for people with a rare and aggressive type of thyroid cancer called anaplastic thyroid cancer. The drugs aim to shrink tumors before surgery and help the immune system fight the cancer.
Chapel Hill, North CarolinaAges 18 years+ - NCT06906562RecruitingPhase 2
Pemigatinib for advanced pancreatic cancer with FGFR changes
This trial tests a targeted pill, pemigatinib, for people with advanced pancreatic cancer that has a specific FGFR gene change. The study is done entirely through telemedicine, so you can participate from home if eligible.
Charlotte, North CarolinaAges 18 years+ - NCT06902311RecruitingPhase 2
Shorter radiation after lumpectomy for early breast cancer
This trial tests a shorter, more intense course of daily radiation therapy (called ultra hypo-fractionation) given after lumpectomy for early-stage breast cancer. The goal is to reduce the number of treatment visits while keeping the same high level of effectiveness and safety.
Chapel Hill, North CarolinaAges 50 years+ - NCT06890338RecruitingPhase 2
Carboplatin and mirvetuximab for advanced ovarian cancer
This trial tests a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) given through a vein. It is for people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific protein called folate receptor alpha (FRα) on at least 75% of tumor cells.
Chapel Hill, North CarolinaAges 18 years+ - NCT06876714RecruitingPhase 3
Shorter vs Longer HER2 Therapy for Breast Cancer with Complete Response
This trial compares 6 months versus 12 months of HER2-targeted therapy for people with HER2+ breast cancer who had a complete response after chemo and trastuzumab. The goal is to see if a shorter treatment is just as effective.
Cary, North CarolinaAges 18 years+ - NCT06878547Recruiting
Ultrasound study for breast cancer tissue structure
This study uses a special ultrasound technique (VisR) to look at the structure of breast tissue and collagen in women with suspicious or known breast cancer. The goal is to see if this imaging can help doctors better understand breast cancer without needing a biopsy.
Chapel Hill, North CarolinaAges 20–90 - NCT06864338Recruiting
Pilot study for a new colorectal cancer screening test
This study tests a new stool-based test for detecting colorectal cancer and advanced polyps. It aims to see how well it works compared to a colonoscopy. The results may lead to a simpler screening option.
Morrisville, North CarolinaAges 18 years+ - NCT06848491Recruiting
Smartphone weight loss programs for young adult cancer survivors
This study tests two different smartphone-based programs to help young adult cancer survivors lose weight. Participants are randomly assigned to one of two programs and use an app to track their progress.
Chapel Hill, North CarolinaAges 18–39 - NCT06840886RecruitingPhase 1
Study of PHST001 for advanced solid tumors
This trial tests an experimental drug called PHST001 for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if PHST001 can help shrink or control the tumor.
Durham, North CarolinaAges 18 years+ - NCT06824467RecruitingPhase 3
Maintenance Therapy Study for Recurrent Ovarian Cancer
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
Pinehurst, North CarolinaAges 18 years+ - NCT06732375Recruiting
Mindset Moments for young adult cancer survivors
This study looks at a simple online program called 'Mindset Moments' to help young adults (ages 19-25) who have finished cancer treatment feel better emotionally. You may join if you're still feeling some distress and want to try a new way to cope.
Durham, North CarolinaAges 19–25 - NCT06690775RecruitingPhase 2
Study of a new drug for platinum-resistant ovarian cancer
This trial tests an investigational drug called TORL-1-23 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if the drug can help shrink or control the cancer.
Durham, North CarolinaAges 18 years+
Cancer trials by city in North Carolina
Where these studies are running in North Carolina
Institutions with a site for the recruiting cancer studies listed above.
- Duke University Medical Center · 6 studies
- University of North Carolina at Chapel Hill · 6 studies
- UNC Lineberger Comprehensive Cancer Center · 4 studies
- FirstHealth of the Carolinas · 3 studies
- Carolina BioOncology Institute · 2 studies
- Duke Cancer Center Cary · 2 studies
- Duke Women's Cancer Care Raleigh · 2 studies
- Southeastern Medical Oncology Center-Clinton · 2 studies
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cancer trials in other states
Common questions
- Are there cancer clinical trials in North Carolina?
- Yes. We're currently tracking 622 recruiting cancer studies with a site in North Carolina, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study in North Carolina?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in North Carolina to take part?
- Not necessarily. These studies have a site in North Carolina, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open in North Carolina regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.